129 related articles for article (PubMed ID: 20689436)
1. Cardiac allograft vasculopathy: do adipocytes bridge alloimmune and metabolic risk factors?
Wehner JR; Baldwin WM
Curr Opin Organ Transplant; 2010 Oct; 15(5):639-44. PubMed ID: 20689436
[TBL] [Abstract][Full Text] [Related]
2. Immunology insights into cardiac allograft rejection.
Savasta M; Lentini S
Rev Cardiovasc Med; 2011; 12(2):e68-76. PubMed ID: 21796085
[TBL] [Abstract][Full Text] [Related]
3. Assessment of immunological markers as mediators of graft vasculopathy development in heart transplantation.
Mirabet S; Gelpí C; Roldán C; Brossa V; Mendoza CA; Lopez L; Molto E; Alvaro Y; Martinez V; Padró JM; Roig E
Transplant Proc; 2011; 43(6):2253-6. PubMed ID: 21839249
[TBL] [Abstract][Full Text] [Related]
4. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response.
van Loosdregt J; van Oosterhout MF; Bruggink AH; van Wichen DF; van Kuik J; de Koning E; Baan CC; de Jonge N; Gmelig-Meyling FH; de Weger RA
Circulation; 2006 Oct; 114(15):1599-607. PubMed ID: 17015796
[TBL] [Abstract][Full Text] [Related]
5. The role of histoincompatibility in cardiac allograft vasculopathy.
Costanzo MR
J Heart Lung Transplant; 1995; 14(6 Pt 2):S180-4. PubMed ID: 8719482
[No Abstract] [Full Text] [Related]
6. Cellular and humoral immunity to vascular endothelium and the development of cardiac allograft vasculopathy.
Hosenpud JD; Everett JP; Morris TE; Wagner CR; Shipley GD
J Heart Lung Transplant; 1995; 14(6 Pt 2):S185-7. PubMed ID: 8719483
[No Abstract] [Full Text] [Related]
7. Cardiac allograft vasculopathy: recent developments.
Schmauss D; Weis M
Circulation; 2008 Apr; 117(16):2131-41. PubMed ID: 18427143
[TBL] [Abstract][Full Text] [Related]
8. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy.
Bayliss J; Bailey M; Leet A; Stein AN; Thomson NM; McLean CA
Transplantation; 2008 Oct; 86(7):991-7. PubMed ID: 18852667
[TBL] [Abstract][Full Text] [Related]
9. Development of a combined heart and carotid artery transplant model to investigate the impact of acute rejection on cardiac allograft vasculopathy.
Soleimani B; Fu F; Lake P; Shi VC
J Heart Lung Transplant; 2008 Apr; 27(4):450-6. PubMed ID: 18374883
[TBL] [Abstract][Full Text] [Related]
10. Cardiac allograft vasculopathy: a donor or recipient induced pathology?
van den Hoogen P; Huibers MM; Sluijter JP; de Weger RA
J Cardiovasc Transl Res; 2015 Mar; 8(2):106-16. PubMed ID: 25652948
[TBL] [Abstract][Full Text] [Related]
11. Cardiac allograft vasculopathy: pathology, prevention and treatment.
Kass M; Haddad H
Curr Opin Cardiol; 2006 Mar; 21(2):132-7. PubMed ID: 16470150
[TBL] [Abstract][Full Text] [Related]
12. The experimental study of cardiac allograft vasculopathy and myocardial fibrosis in rats.
Song G; Zhang J; Jiang D; Wang X; Xu J
Transplant Proc; 2008 Oct; 40(8):2712-5. PubMed ID: 18929843
[TBL] [Abstract][Full Text] [Related]
13. Allosensitization in bridge to transplant Novacor left ventricular assist device patients: analysis of long-term outcomes with regard to acute rejection and chronic allograft vasculopathy.
Kirsch L; Timmermans T; Van Caenegem O; Gurne O; Noirhomme P; Jacquet LM; Latinne D; Poncelet AJ
Eur J Cardiothorac Surg; 2008 Aug; 34(2):268-74; discussion 274. PubMed ID: 18456505
[TBL] [Abstract][Full Text] [Related]
14. Effect of single-dose rapamycin-based immunosuppression on the development of cardiac allograft vasculopathy.
Goggins WC; Fisher RA; Cohen DS; Tawes JW; Grimes MM
J Heart Lung Transplant; 1996 Aug; 15(8):790-5. PubMed ID: 8878761
[TBL] [Abstract][Full Text] [Related]
15. Neointimal inflammation and adventitial angiogenesis correlate with severity of cardiac allograft vasculopathy in pediatric recipients.
Seipelt IM; Pahl E; Seipelt RG; Mavroudis C; Backer CL; Stellmach V; Cornwell M; Crawford SE
J Heart Lung Transplant; 2005 Aug; 24(8):1039-45. PubMed ID: 16102439
[TBL] [Abstract][Full Text] [Related]
16. Macrophages and transplant arteriosclerosis: known and novel molecules.
Russell ME
J Heart Lung Transplant; 1995; 14(6 Pt 2):S111-5. PubMed ID: 8719472
[No Abstract] [Full Text] [Related]
17. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation.
Mahle WT; Vincent RN; Berg AM; Kanter KR
J Heart Lung Transplant; 2005 Jan; 24(1):63-6. PubMed ID: 15653381
[TBL] [Abstract][Full Text] [Related]
18. Predominant expression of the Th2 response in chronic cardiac allograft rejection.
Mhoyan A; Wu GD; Kakoulidis TP; Que X; Yolcu ES; Cramer DV; Shirwan H
Transpl Int; 2003 Aug; 16(8):464-73. PubMed ID: 12712237
[TBL] [Abstract][Full Text] [Related]
19. Cardiac allograft vasculopathy: a review.
Ramzy D; Rao V; Brahm J; Miriuka S; Delgado D; Ross HJ
Can J Surg; 2005 Aug; 48(4):319-27. PubMed ID: 16149368
[TBL] [Abstract][Full Text] [Related]
20. Acute rejection: culprit or coincidence in the pathogenesis of cardiac graft vascular disease?
Hauptman PJ; Nakagawa T; Tanaka H; Libby P
J Heart Lung Transplant; 1995; 14(6 Pt 2):S173-80. PubMed ID: 8719481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
